Tara Haelle

2 days ago | oncologynewscentral.com | Tara Haelle

Niraparib with abiraterone acetate plus prednisone (AAP) reduced the risk for radiographic progression in patients with metastatic castration-sensitive prostate cancer (mCSPC) who had homologous recombination repair (HRR) gene alterations. Findings from the phase 3 randomized, controlled AMPLITUDE trial were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA5006).

4 days ago | oncologynewscentral.com | Tara Haelle

Daily adjuvant aspirin did not improve disease-free survival (DSF) or reduce recurrence in patients with colorectal cancer liver metastases, and resulted in more adverse events. Findings from the phase 3 randomized controlled ASAC trial were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA3511). Among 428 patients, 137 DSF events occurred in those receiving aspirin compared with 131 events in those receiving placebo.

5 days ago | medscape.com | Tara Haelle

As a young child in the 1980s, Jiwa Farrell earned the moniker “Little Apple Cheeks” because her face was always so “cute and pink.” But by the time she was 6 years old, she had already begun recognizing that something else distinguished her from other kids besides her bright pink complexion. “I had flu-like symptoms all throughout my childhood and always felt very fatigued,” Farrell told Medscape Medical News.

1 week ago | oncologynewscentral.com | Tara Haelle

The investigational drug vepdegestrant, a selective proteolysis-targeting chimera (PROTAC), significantly improved progression-free survival (PFS) compared with fulvestrant (Faslodex) in patients with ESR1-mutated, estrogen receptor (ER)-positive, HER2-negative advanced breast cancer that progressed after first-line therapy. Findings from the phase 3 VERITAC-2 trial were presented as part of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA1000).

1 week ago | medscape.com | Tara Haelle

MINNEAPOLIS — The partners of pregnant patients may be more likely to get vaccinated against pertussis, COVID-19, and influenza if prenatal providers recommend it to them, according to a study presented at the American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Meeting.